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mrc-hnr.cam.ac.ukAbstractElevated C-terminal fibroblast growth factor 23 (C-FGF23) concentrations have been
reported in Gambian children with and without putative Ca-deficiency rickets. The aims
of this study were to investigate whether i) elevated C-FGF23 concentrations in Gambian
children persist long term; ii) they are associated with higher intact FGF23 concentrations
(I-FGF23), poor iron status and shorter 25-hydroxyvitamin D half-life (25OHD-t1/2); and iii) the
persistence and predictors of elevated FGF23 concentrations differ between children with
and without a history of rickets. Children (8–16 years, nZ64) with a history of rickets and
a C-FGF23 concentration O125 RU/ml (bone deformity (BD), nZ20) and local community
children with a previously measured elevated C-FGF23 concentration (LCC, nZ20) or
a previously measured C-FGF23 concentration within the normal range (LCK, nZ24)
participated. BD children had no remaining signs of bone deformities. C-FGF23
concentration had normalised in BD children, but remained elevated in LCC children.
All the children had I-FGF23 concentration within the normal range, but I-FGF23
concentration was higher and iron status poorer in LCC children. 1,25-dihydroxyvitamin D
was the strongest negative predictor of I-FGF23 concentration (R2Z18%; PZ0.0006) and
soluble transferrin receptor was the strongest positive predictor of C-FGF23 concentration
(R2Z33%; P%0.0001). C-FGF23 and I-FGF23 concentrations were poorly correlated with
each other (R2Z5.3%; PZ0.07). 25OHD-t1/2 was shorter in BD children than in LCK children
(mean (S.D.): 24.5 (6.1) and 31.5 (11.5) days respectively; PZ0.05). This study demonstrated
that elevated C-FGF23 concentrations normalised over time in Gambian children with a
history of rickets but not in local children, suggesting a different aetiology; that children
with resolved rickets had a shorter 25OHD-t1/2, suggesting a long-standing increased
expenditure of 25OHD, and that iron deficiency is a predictor of elevated C-FGF23
concentrations in both groups of Gambian children.Key Words
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(2014) 3, 1–10IntroductionElevated plasma C-terminal fibroblast growth factor 23
(C-FGF23) concentrations have been recorded in Gambian
children with putative Ca-deficiency rickets (1) and, at alower prevalence, in apparently healthy children from the
local community (2). FGF23 is a bone-derived phosphate
(P)-regulating hormone that acts primarily in the proximalsed under a Creative Commons
nported License.
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a predictor of mortality in patients with renal failure (3).
FGF23 together with its co-receptor a-Klotho (4) binds to
the FGF receptor (FGFR) to initiate the internalisation of
sodium P transporters NaPi-2a (SLC34A1) and NaPi-2c
(SLC34A3) (5). In diseased states where FGF23 concen-
tration is elevated, the net result is an increased urinary
P excretion through a decreased reabsorption of P from the
glomerular filtrate.
As well as having direct effects on P metabolism,
FGF23 targets enzymes involved in vitamin D metabolism.
These include cytochrome P450 enzymes CYP27B1 and
CYP24A1. CYP27B1 is expressed in the kidney and
hydroxylates 25-hydroxyvitamin D (25OHD) to the
active vitamin D metabolite 1,25-dihydroxyvitamin D
(1,25(OH)2D). CYP24A1 is expressed in a variety of tissues
including the liver and the kidney and hydroxylates
25OHD to 24,25-dihydroxyvitamin D (24,25(OH)2D)
and 1,25(OH)2D to 1,24,25-trihydroxyvitamin D
(1,24,25(OH)3D) and to further downstream metabolites.
FGF23 down-regulates the activity of CYP27B1 and
increases the activity of CYP24A1 (6, 7). Conversely,
1,25(OH)2D is a known stimulator of FGF23 production,
and two human studies have shown that vitamin D
administration can modulate circulating FGF23 concen-
tration (8, 9).
Circulating FGF23 concentration is commonly
measured using one of two commercially available assays:
the Kainos intact FGF23 (I-FGF23) assay and the Immuno-
topics C-FGF23 assay. The I-FGF23 assay detects the
full-length protein, whereas the C-FGF23 assay binds to
epitopes within the C-terminal region of the FGF23 protein
and therefore detects both the full-length protein and
C-terminal fragments. The C-terminal end of the I-FGF23
protein contains the motif required for binding to the
de novo a-Klotho–FGFR-binding site, which subsequently
allows for the remaining N-terminus of the FGF23 protein
to activate the FGFR and to initiate a signal (10). Therefore,
the full-length I-FGF23 protein is considered to be the
biologically active form of the FGF23 hormone (11). The
C-terminal fragment is generally regarded as inactive,
although there is some evidence to suggest that C-terminal
fragments may have anti-phosphaturic effects in mice (10)
or conversely phosphaturic activity in rats (12). In
addition, there is a growing body of evidence showing
associations between C-FGF23 concentration and iron
status (2, 13, 14, 15, 16, 17).
As well as being regulated by FGF23, 1,25(OH)2D
production is controlled by parathyroid hormone (PTH)
(18). PTH is secreted by the parathyroid glands in responsehttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0070
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Published by Bioscientifica Ltdto low circulating ionised Ca concentration and PTH
promotes CYP27B1 activity. Dietary Ca intake is known to
be ubiquitously low in Gambia, and factors that may
reduce intestinal Ca absorption such as Helicobacter pylori
infection (19) and intestinal malabsorption are prevalent
in Gambian infants (20). It has been shown that states of
Ca deficiency can increase the demand for 25OHD (21).
It is, therefore, plausible that circulating FGF23 concen-
tration and dietary intake and absorption of Ca may alter
the rate at which 25OHD is utilised.
The aims of this study were to determine longitudinal
changes in C-FGF23 concentration and cross-sectional
predictors of I-FGF23 and C-FGF23 concentrations in
Gambian children with and without a history of rickets
and to determine whether circulating FGF23 concen-
tration and dietary Ca intake are determinants of the
half-life of 25-hydroxyvitamin D (25OHD-t1/2).Subjects and methods
Study approvals and consent
Written informed consent was obtained from the parents
of the children involved in the study. Ethical approval was
given by the Gambian Government/MRC Laboratories
Joint Ethics Committee.
Subjects and study design
All children had participated in a previous study con-
ducted at MRC Keneba 3.2–5.8 years earlier (2, 13).
Children aged between 8.0 and 16.0 years were recruited
on the basis of a previously determined plasma C-FGF23
concentration with or without a history of rickets-
like bone deformities and were allocated to one of
three groups. A concentration of C-FGF23 O125 RU/ml
(C-FGF23: Immutopics, Inc., San Clemente, CA, USA) was
considered elevated. The original diagnosis of rickets was
made on the basis of physical signs consistent with rickets
and radiographic evidence of rickets and/or an elevated
concentration of alkaline phosphatase (1). The children
were treated with Ca and vitamin D, which was
subsequently terminated after 12 months (1). The bone
deformity (BD) group consisted of children with a history
of rickets-like bone deformities and a previously measured
C-FGF23 concentration O125 RU/ml. The LCC group
consisted of local community (LC) children with no
history of rickets-like bone deformities but had a pre-
viously measured C-FGF23 concentration O125 RU/ml.
Finally, the LCK group consisted of LC children with noThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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3–10 3 :3history of rickets-like bone deformities and a previously
measured C-FGF23 concentration within the normal
range (25–125 RU/ml). Children in the LC groups were
also selected to age- and sex-match the children in the BD
group. None of the children were on current medication or
were receiving supplements.Anthropometry
Weight was measured to the nearest 0.1 kg using a
calibrated electronic scale (HD-305 Tanita, Tanita Europe
BV, Naarden, The Netherlands). Standing height and
sitting height were measured to the nearest 0.1 cm using
a portable stadiometer (Leicester Height Measure, SECA,
Hamburg, Germany). Whole-body fat and trunk fat were
measured by impedance using a Tanita scale (BC-418MA
Tanita, Tanita Europe BV) and expressed as a percentage of
total body or trunk mass.Fasting blood and urine collection
An overnight-fasted 2-h urine sample and with a mid-point
lithium-heparin (LiHep)and EDTA bloodsample and a non-
fasting 24-h urine sample were obtained as described
previously (13). Blood ionised Ca concentration adjusted
to a pH of 7.4 (iCa) and derived Hb concentration were
measured in whole LiHep-blood samples (ABL77, Radio-
meter Ltd, Crawley, West Sussex, UK) within 10 min of
collection. Plasma was separated from whole blood by
centrifugation at 4 8C (20 min at 1800 g) within 30 min and
subsequently frozen atK70 8C. The EDTA pellet was used to
determine zinc protoporphyrin (ZnPP) concentration on a
haematofluorometer (ZPP 206d, Aviv Biomedical, Inc.,
Lakewood, NJ, USA). Acidified (HCl, 10 ml/ml, laboratory
reagent grade SD 1.18, Fisher Scientific, Gillingham, Kent,
UK) urine aliquots were stored at K20 8C. All the frozen
samples were sent on dry ice to MRC Human Nutrition
Research (HNR), Cambridge, UK, and plasma samples were
stored atK70 8C and urine samples atK20 8C until analysis.Biochemical analysis
The plasma samples were analysed for markers of
vitamin D, Ca and P metabolism, iron status and
inflammation, and renal and liver function, using com-
mercially available methods according to the manufac-
turers’ instructions. EDTA-plasma samples were used
to determine FGF23 concentration by ELISA (C-FGF23:
Immutopics, Inc., and I-FGF23 (22): Kainos, Tokyo, Japan)
and intact PTH concentration by IRMA (Immulite, Siemenshttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0070
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Published by Bioscientifica LtdHealthcare Diagnostics, Camberley, Surrey, UK). Concen-
trations of C-FGF23 O125 RU/ml or I-FGF23 O52 pg/ml
were considered elevated (23). LiHep-plasma samples were
used for the other assays. These included determination
of 25OHD (Diasorin, Stillwater, MN, USA) and 1,25(OH)2D
(IDS, Boldon, Tyne & Wear, UK) concentrations by RIA and
soluble transferrin receptor (sTfR; Ramco Laboratories,
Inc., Stafford, TX, USA) concentration by ELISA.
A concentration of 25OHD of !25 nmol/l was taken as
an indicator of an increased risk of vitamin D-deficiency
rickets (24, 25). Total Ca, P, Mg, Cr, albumin (alb), total
alkaline phosphatase (TALP) and cystatin C (cys C)
concentrations were measured using commercially avail-
able colorimetric methods (Dimension Clinical Chemistry
Systems, Siemens Healthcare Diagnostics, Camberley,
Surrey, UK), C-reactive protein (CRP) concentration by
particle-enhanced turbidimetric immunoassay, and a-1-
acid glycoprotein (AGP) and ferritin (Ferr) concentrations
by ELISA (Dimension Clinical Chemistry Systems, Siemens
Healthcare Diagnostics). Ca, P and Cr concentrations were
determined in the acidified 2- and 24-h urine samples using
colorimetric methods as used for the plasma samples.
Urinary Ca and P concentrations are expressed as molar
ratios to Cr concentration.
Assay accuracy and precision were monitored across
the working range of the assays using reference materials
provided by the manufacturer or by external quality
assurance schemes. Quality assurance for PTH was
monitored by the National External Quality Assessment
Service (Department of Clinical Biochemistry, Royal
Infirmary, Edinburgh, UK) and for 25OHD and
1,25(OH)2D by the Vitamin D External Quality Assess-
ment Scheme (Endocrine/Oncology Laboratory, Charring
Cross Hospital, London, UK). For sTfR, the internal
standard for quality assessment (QA) was an in-house
human plasma sample and the external standard for
QA was obtained from the Centre for Disease Controls
(CDC) USA. For all other analyses, in-house standards
were used for QA.Dietary assessment, infection status and
intestinal integrity
Two-day weighed dietary assessment was conducted using
Gambian food composition tables (26) in the same way as
described previously (13).
H. pylori infection was determined using a non-invasive
stable isotope urea breath test. Fifty micrograms of 13C-urea
(Cambridge Isotopes, Tewsbury, MA, USA) in a 100 ml
solution of polycal (10% w/v, Nutricia, Trowbridge,This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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breath samples were collected into gas tubes (12 ml, Labco
Ltd., Ceredigion, UK) from overnight-fasted subjects, after
which the subjects were provided with the urea dose to
drink. After 30 min, two more breath samples were
collected. The gas tubes were kept at room temperature
and were analysed at MRC HNR using isotope ratio mass
spectrometry (IRMS) (AP2003 IRMS, Analytical Precision
Products, Ltd., Cambridge, UK). A delta over baseline (DOB)
O5.47‰ was considered to be indicative of the presence of
H. pylori (27).
Intestinal integrity was assessed using the lactulose:
mannitol (L:M) intestinal permeability test. The test dose
consisted of lactulose (4 g; Sandoz, Camberley, Surrey, UK)
and mannitol (1 g; Sigma–Aldrich, Gillingham, Kent, UK)
made up to 20 ml with water. Following the completion of
the 2-h urine collection period, the subjects were
instructed to drink the test solution and their urine was
collected during the following 5 h into containers
containing a few drops of chlorhexidine antiseptic solution
(5% w/v, Holden Medical, Lelystad, The Netherlands) to
prevent bacterial contamination and sugar degradation. At
the end of the 5-h urine collection period, urine aliquots
were frozen atK20 8C, transported to MRC HNR on dry ice,
stored at K20 8C and assayed using in-house methods
described elsewhere (20, 28). A mannitol absorption of
!14% was taken to indicate malabsorption and partial
villus atrophy, and a lactulose absorptionO1% was taken
to indicate disaccharide hyperpermeability (29).25OHD half-life
25OHD-t1/2 was determined using the 25OHD terminal
slope principle described elsewhere (30) in a subset of
children (BD nZ12, LCCnZ12, and LCK nZ13). 3-2H-
25-hydroxyvitamin D3 (6, 19, 19-d3) (d3-25OHD3) (Sigma–
Aldrich; 97 atom % D, 98% (CP)) was dissolved in vegetable
oil and a dose (40 nmol) was given on a small piece of bread
after the fasting blood sample was collected (day 1). Further
fasting LiHep-blood samples were collected on days 6, 9,
21, 24 and 30. Plasma samples were frozen atK70 8C and
analysed at MRC HNR. The samples were subjected to
solid-phase extraction and derivatisation with 50 ml
4-phenyl-1,2,4-triazoline-3,5-dione (0.5 mg/ml) solution
in acetonitrile as described elsewhere (30). Analyses were
carried out using a UPLC system (LC-20 AS, Shimadzu Ltd.,
Milton Keynes, UK) interfaced to an ABSciex 5500 QTRAP
mass spectrometer (MDS Analytical Technologies, Con-
cord, ON, Canada). The MS was operated in electrospray
ionisation (ESI) positive mode with multiple reactionhttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0070
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Published by Bioscientifica Ltdmonitoring (MRM). Derivatised sample extracts (10 ml)
were injected into an Acquity UPLC BEH C18 column (2.1!
100 mm, 1.7 mm, Waters, Elstree, Hertfordshire, UK)
maintained at 45 8C. Mobile phases were eluent A (0.1%
formic acid and 5 mM methylamine in H2O) and eluent B
(0.1% formic acid in a mixture of methanol:H2-
O:acetonitrile (97:2:1, v/v/v)). The software used for system
control and chromatogram integration was Analyst ver-
sion 1.5.2 (Applied Biosystems, Concord, ON, Canada).
25OHD-t1/2 was calculated from the terminal slope of the
disappearance of d3-25OHD3 using the following equation
t1 ⁄2Zln(2)/kB, where kB is the natural logarithm of the slope
of the line of best fit calculated from d6 to d30 (30).Statistical analyses and calculations
All the statistical analyses were carried out using DataDesk
6.3 (Data Description, Inc., Ithaca, NY, USA). Positively
skewed variables were transformed using natural logari-
thms before statistical tests. Summary statistics are
expressed as mean (S.D.) for normally distributed variables
or as geometric mean (K1S.D.,C1S.D.) for skewed variables.
For continuous variables, group differences were assessed
using age- and sex-corrected regression analysis for two
groups or with ANOVA followed by two-sample Student’s
t-tests. For categorical variables, group differences were
identified using c2 tests. For analysis of predictors of
25OHD-t1/2, I-FGF23 and C-FGF23, multiple regression
with stepwise backwards elimination was conducted
without correcting for age or sex. With the variables
expressed as natural logarithms, the coefficient (S.E.M.) for
a group difference !100 closely equates to the difference
expressed as a sympercent (S.E.M.) (31). Longitudinal
analysis of C-FGF23 was conducted using conditional
regression, whereby the change (DZln PreviousC-FGF23K
ln BaselineC-FGF23) was the dependent variable and baseline
C-FGF23 concentration and baseline age were corrected
for. In this exploratory study, P%0.05 was considered to
be statistically significant and no adjustments were made
to account for the number of tests carried out.
Glomerular filtration rate (eGFR) was estimated in the
following way using plasma cys C (32):
eGFRZ
74:835
cys C ðmg=mlÞ1=0:75
 
Tubular maximal reabsorption of P (TmP:GFR) was
calculated in the following way (33):
TRPZ1K
uP
pP
 
!
pCr
pCr
  This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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5–10 3 :5for TRP %0.86, then TmP:GFRZTRP!pP, or for TRP
O0.86, then:
TmP : GFRZ
0:3!TRP
1Kð0:8!TRPÞ
 
!pP
The percentage absorption of L was calculated in the
following way:
%LZ
uL concentration ðmg=mlÞ!u volume ðmlÞ
L in dose ðmgÞ
%M was calculated in the same way.Results
Anthropometry
BD children no longer had visible signs of bone deform-
ities, and there was no significant difference in age, height,
sitting height or weight between the three groups
(Table 1). BD children had a greater percentage of
total body fat and percentage of trunk fat mass than LC
children (%total body fat: BDZ16.9 (4.5), LCCZ15.6
(3.1), and LCKZ14.7 (3.7); ANOVA PZ0.01; %trunk fat
mass: BDZ12.4 (3.5), LCCZ9.9 (2.3), and LCKZ9.7
(2.9); ANOVA PZ0.004) (Table 1).Concentration and predictors of FGF23
In BD children, C-FGF23 concentration had decreased
significantly since the previous C-FGF23 concentration
measurement (obtained mean (S.D.) 4.9 (0.5) years before).
The percentage of BD children with an elevated C-FGF23
concentration (O125 RU/ml) decreased from 100 to 25%
(BD geometric mean (K1S.D., C1S.D.) C-FGF23: from 536
(167, 1715) to 85 (53, 140) RU/ml; conditional regression
PZ0.01) (Fig. 1A). By contrast, there was no significant
change in C-FGF23 concentration in LCC children (from
252 (125, 509) to 230 (87,608) RU/ml; conditional regression
PZ0.2).C-FGF23concentrationremainedelevated in70%of
the LCC children. There was no significant change over time
in LCK children (58 (42, 79) to 79 (37, 170) RU/ml;
conditional regression PZ0.3). Consequently, C-FGF23
concentration at this follow-up was significantly higher in
LCC children than in either BD or LCK children (ANOVA
P%0.0001), but was not significantly different between BD
and LCK children (Table 1).
All children had an I-FGF23 concentration within the
normal range, but I-FGF23 concentration was higher in
LCC children than in BD children (BDZ25.7 (19.2, 34.5),
LCCZ34.3 (22.8, 51.5), and LCKZ28.2 (19.6, 40.7)
pg/ml; PZ0.05) (Table 1).http://www.endocrineconnections.org
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Published by Bioscientifica LtdC-FGF23 concentration did not significantly correlate
with I-FGF23 concentration when all the groups were
combined (nZ64) (coefficient % (S.E.M.): 8.2 (4.0) %;
R2Z5.3%; PZ0.07). However, C-FGF23 was a significant
predictor of I-FGF23 concentration in BD children
(coefficient % (S.E.M.): 30 (12) %; R2Z24%; PZ0.03)
but not in LC children (coefficient % (S.E.M.):
LCCZK2.5 (6.5)%; R2Z0.8%; PZ0.7; LCKZ6.4
(10.3)%; R2Z1.7%; PZ0.5) (Fig. 1B).
There was biochemical evidence that LCC children
had poorer iron status compared with the other two
groups as demonstrated by higher ZnPP and sTfR
concentrations compared with those in BD and LCK
children (Table 1).
1,25(OH)2D was the strongest predictor of I-FGF23
concentration (nZ64; coefficient % (S.E.M.): K4.7 (1.0)%;
R2Z18.1%; PZ0.0006) (Fig. 1C) but not of C-FGF23
concentration (nZ64; coefficient % (S.E.M.):K25.4
(44.2)%; R2Z0.5%; PZ0.6) in univariate analyses. sTfR
was the strongest predictor of C-FGF23 concentration
(nZ64; coefficient % (S.E.M.): 132 (24) %; R2Z33.2%;
P%0.0001) (Fig. 1D), but it did not predict I-FGF23
concentration (nZ64; coefficient % (S.E.M.): 8.6 (10.5) %;
R2Z1.1%; PZ0.4) in univariate analyses.
Using stepwise elimination in multivariate analysis,
1,25(OH)2D and 25OHD were found to be the only
predictors of I-FGF23 concentration (among C-FGF23,
PTH, P, iCa, sTfR, Ferr, Hb, ZnPP, TmP:GFR, eGFR,
and dietary Ca and phosphorus intake, which were
not significant). 1,25(OH)2D and 25OHD remained in
the model and together predicted 28.5% of the varia-
tion in I-FGF23 concentration, whereas only sTfR
and Ferr remained in the model for C-FGF23 and
together predicted 45.0% of the variation in C-FGF23
concentration.Dietary Ca intake and factors affecting Ca absorption
Mean dietary Ca intake was 265 (12.6) mg/day and did
not differ significantly between the groups (mean (S.D.)
mg/day: BDZ259 (129), LCCZ273 (133), and LCKZ263
(108); ANOVA PZ0.9). There were also no significant
differences in phosphorus (Table 1), energy or protein
intake (data not shown).
Eighty-five percentage of all children were identi-
fied as having an H. pylori infection, and there was no
difference in the prevalence of infection between the
groups (H. pylori infection %: BDZ84%, LCCZ80%, and
LCKZ91%; c2 PZ0.6). L:M test indicated signs of
intestinal malabsorption in the majority of childrenThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
Table 1 Differences in anthropometry, biochemical profile and dietary indices by group.
Dependent BD LCC LCK ANOVA
Variable nZ20 nZ20 nZ24 P value
Anthropometry
Age (years) 11.9 (2.4) 12.3 (2.5) 12.3 (2.3) 0.8
Sex (F/M) 7/13 12/8 7/17 0.1
Height (cm) 141.4 (14.9) 142.7 (14.3) 143.7 (12.7) 0.8
Sitting height (cm) 70.8 (6.2) 71.4 (5.4) 72.2 (6.0) 0.6
Weight (kg) 32.2 (9.7) 31.5 (9.5) 32.3 (9.2) 0.4
BMI (kg/m2) 15.7 (2.0)b 15.0 (1.9)a 15.3 (2.1) 0.1
% Fat Tanita 16.9 (4.5)b 15.6 (3.1)a 14.7 (3.7) 0.01
% Trunk fat mass 12.4 (3.5)b,c 9.9 (2.3)a 9.7 (2.9)a 0.004
Plasma biochemistry
iCa (7.4) (mmol/l) 1.13 (0.02) 1.14 (0.03) 1.13 (0.03) 0.7
Ca (mmol/l) 2.32 (0.04) 2.34 (0.07) 2.32 (0.05) 0.2
25OHD (nmol/l) 61.1 (16.8) 62.1 (16.5) 57.8 (13.8) 0.6
25OHD-t1/2 (days) 24.5 (6.1)
c 27.8 (6.4) 31.5 (11.5)a 0.09
1,25(OH)2D (pmol/l) 339.9 (71.4) 352.7 (84.0) 301.5 (79.4) 0.1
PTH (pg/ml) 41.0 (19.4) 39.9 (18.8) 35.9 (21.9) 0.6
PO4
3K (mmol/l) 1.48 (0.17) 1.47 (0.17) 1.56 (0.15) 0.3
C-FGF23*(RU/ml) 84.7 (53.7, 140.0)b 229.8 (86.9, 607.4)a,c 78.9 (37.3, 166.9)b 0.0001
I-FGF23*(pg/ml) 25.7 (19.2, 34.5)b 34.3 (22.8, 51.5)a 28.2 (19.6, 40.7) 0.05
TALP (U/l) 321.6 (73.2) 348.9 (108.7) 362.3 (107.2) 0.4
Cys C (mg/l) 0.81 (0.15)c 0.86 (0.15)c 0.99 (0.17)a,b 0.002
Cr (mmol/l) 47.2 (8.5) 43.3 (7.0) 46.5 (10.4) 0.2
Albumin (g/l) 38.5 (2.3) 38.6 (2.9) 37.4 (2.4) 0.2
Hb*(g/dl) 13.4 (12.4, 14.4) 12.6 (10.4, 15.3) 13.3 (12.3, 14.3) 0.2
ZnPP*(mmol/mol per haem) 69.4 (51.2, 93.9)b 99.8 (66.2, 150.7)a,c 68.8 (50.2, 94.2)b 0.008
Ferr*(mg/l) 31.6 (15.5, 40.7) 20.2 (8.30, 48.9) 29.7 (17.0, 51.9) 0.2
sTfR*(mg/ml) 4.91 (3.96, 6.09)b 7.45 (4.48, 6.09)a,c 4.89 (3.90, 6.11)b 0.0001
AGP (mmol/l) 17.0 (5.6) 18.3 (5.7) 18.2 (3.9) 0.5
CRP*(mg/dl) 2.12 (0.74, 6.07) 2.32 (0.99, 4.45) 2.38 (0.99, 5.48) 0.9
Mg (mmol/l) 0.85 (0.06) 0.85 (0.07) 0.84 (0.08) 0.5
eGFR and mineral excretion
eGFR (ml/min) 102.2 (22.6)c 95.5 (22.8) 78.8 (17.2)a 0.002
TmP:GFR (mmol/l) 1.82 (0.29)c 1.88 (0.20) 1.98 (0.21)a 0.08
2-h uPO4
3K:Cr*(mol/mol) 1.29 (0.80, 2.08) 0.93 (0.47, 1.83) 1.20 (0.87, 1.64) 0.1
2-h uCa:Cr*(mol/mol) 0.35 (0.15, 0.81) 0.29 (0.16, 0.51) 0.87 (0.46, 1.65) 0.4
24-h uPO4
3:Cr*(mol/mol) 1.98 (1.44, 2.74) 1.92 (1.44, 2.55) 1.83 (1.18, 2.83) 0.7
24-h uCa:Cr*(mol/mol) 0.32 (0.16, 0.67) 0.24 (0.14, 0.42) 0.26 (0.13, 0.50) 0.5
Two-day weighed dietary intake
Ca (mg) 259 (129) 273 (133) 263 (108) 0.9
Phosphorus (mg) 679 (267) 722 (315) 671 (260) 0.5
Ca/P (mol/mol) 0.30 (0.11) 0.30 (0.12) 0.32 (0.10) 0.8
BD, history of rickets and a previously measured elevated C-terminal FGF23 (C-FGF23) concentration; LCC, local controls with a previously measured high
C-FGF23 concentration; and LCK, local controls with a previously measured normal C-FGF23 concentration. All measurements were conducted on the entire
dataset (nZ64), with the exception of 25OHD half-life (25OHD-t1/2), which was conducted on a subset (BD: nZ12, LCC: nZ12, and LCK: (nZ13)). For
normally distributed data, the results are mean (S.D.); for positively skewed data (denoted by *), the results are geometric mean (K1S.D.,CS.D.). The ANOVA
P value is age- and sex-adjusted with the exception of the sex variable, which is a c2 P value. Significant differences between the groups as determined by
two-sample Student’s t-tests are denoted by a superscript, i.e. aZ significantly different from BD, bZsignificantly different from LCC, and cZsignificantly
different from LCK.
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6–10 3 :6(%M !14 in 88% of the children), and this distribution
was similar across all the three groups (%M %14:
BDZ90%, LCCZ84%, and LCKZ92%; c2 PZ0.7). The
percentage recovery of L was within the normal range
(!1%) in the majority of children (%L !1 in 96% of
the children), and this distribution was similar across all
the three groups (%L !1: BDZ100%, LCCZ89%, and
LCKZ100%; c2PZ0.1).http://www.endocrineconnections.org
DOI: 10.1530/EC-13-0070
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Published by Bioscientifica Ltd25OHD half-life
There were no significant differences in anthropometry,
biochemical profile or dietary intake between those who
did and did not participate in the 25OHD-t1/2 analysis,
with the exception of plasma alb and AGP concentra-
tions (alb concentration was w1.6 g/l higher and AGP
concentration w2.2 mmol/l lower in those who didThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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7–10 3 :7participate in the 25OHD-t1/2 analysis compared with
those in children who did not).
25OHD-t1/2 was significantly shorter in BD children
(nZ12) than in LCK children (nZ13) (24.5 (6.1) and 31.5
(11.5) days respectively; PZ0.05). 25OHD-t1/2 was not
significantly different between LCC (nZ12) and BD
children (27.8 (6.4) and 24.5 (6.1) days respectively;
PZ0.3) or LCC and LCK children (27.8 (6.4) and 31.510
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Published by Bioscientifica Ltd(11.5) days respectively; PZ0.3). No significant predictors
of 25OHD-t1/2 were identified from among plasma
C-FGF23, I-FGF23, iCa, P, PTH, 1,25(OH)2D, 25OHD or
dietary Ca intake in multiple regression analysis.Discussion
Elevated plasma C-FGF23 concentrations have been
recorded in Gambian children with putative Ca-deficiency
rickets (1) and, at a lower prevalence, in apparently
healthy children from the local community (2). This
longitudinal study of children previously identified to
have an elevated C-FGF23 concentration, with and with-
out putative Ca-deficiency rickets (1), revealed that
C-FGF23 concentration, as well as other biochemical
abnormalities, had normalised in the children with
resolved rickets (BD), whereas C-FGF23 concentration
remained unchanged in apparently healthy controls.
Local controls with a previously measured elevated
C-FGF23 concentration (LCC) had an elevated concen-
tration at follow-up, whereas local controls with a
previously measured normal C-FGF23 concentration
(LCK) had a normal concentration.
I-FGF23 concentration was higher in LCC children
than in BD children, but was within the normal ranges
in all the children. Interestingly, C-FGF23 and I-FGF23Figure 1
Scatterplot of C-terminal FGF23 (C-FGF23) concentrations at baseline
and follow-up (A); C-FGF23 and intact FGF23 concentrations at follow-up
(B);1,25(OH)2D and I-FGF23 concentrations (C); and sTfR and C-FGF23
(D) concentrations by group. BD black triangle, history of rickets and a
previously measured elevated C-FGF23 concentration; LCC grey triangle,
local controls with a previously measured high C-FGF23 concentration;
LCK, local controls with a previously measured normal C-FGF23 concen-
tration. Dotted lines at 125 RU/ml and 52 pg/ml are upper levels of
normal for C-terminal and intact-FGF23 concentrations respectively.
Equations of the line:
All ðnZ64Þ
A : ðln C-FGF23ÞZ 4:1 ð0:5ÞK0:12 ð0:09Þ ðln previous C-FGF23Þ; PZ 0:2:
B : ðln I-FGF23ÞZ2:95 ð0:21ÞK0:08 ð0:04Þ ðln C-FGF23Þ; PZ 0:07:
C : I-FGF23Z 45:43 ð4:43ÞC0:05 ð0:01Þ ð1; 25ðOHÞ2DÞ; PZ 0:0006:
D : ðln C-FGF23ÞZ 2:46 ð0:42ÞK1:32 ð0:24Þ ðln sTfRÞ; P%0:0001:
BD ðnZ 20Þ
A : ðln C-FGF23ÞZ 5:2 ð0:6ÞC0:11 ð0:09Þ ðln previous C-FGF23Þ; PZ0:2:
B : ðln I-FGF23ÞZ1:89 ð0:56ÞK0:30 ð0:12Þ ðln C-FGF23Þ; PZ 0:03:
LCC ðnZ20Þ
A : ðln C-FGF23ÞZ 4:1 ð1:8ÞK0:23 ð0:32Þ ðln previous C-FGF23Þ; PZ 0:5:
B : ðln I-FGF23ÞZ3:59 ð0:36ÞC0:02 ð0:07Þ ðln C-FGF23Þ; PZ0:7:
LCK ðnZ 24Þ
A : ðln C-FGF23ÞZ 0:76 ð1:89ÞK0:88 ð0:46Þ ðln previous C-FGF23Þ; PZ 0:07:
B : ðln I-FGF23ÞZ3:06 ð0:45ÞK0:06 ð0:10Þ ðln C-FGF23Þ; PZ 0:5:
This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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8–10 3 :8concentrations correlated positively in the BD group,
but did not correlate in either of the LC groups or when
the three groups were combined. As well as a persistently
elevated C-FGF23 concentration, LCC children also had
poorer iron status compared with the other children. The
strong association between iron status and C-FGF23
concentration in the LCC group may suggest a role of
iron in FGF23 metabolism.
One of the main findings of this study is that
25OHD-t1/2 in children with a history of rickets (BD) was
shorter than that in children from the local community
(LCK). Despite the facts that their biochemical and bone
abnormalities had normalised and that the children no
longer had significantly elevated PTH, 1,25(OH)2D,
C-FGF23 or TALP concentrations or visible signs of
bone deformities, 25OHD-t1/2 in children with a history
of rickets was w7 days shorter than that in the local
community children, suggestive of a long-standing
increased expenditure of 25OHD. It is possible that BD
children had increased activities of CYP27B1 and/or
CYP24A1, which would in turn increase the rate of
production of 1,25(OH)2D and 24,25(OH)2D and
1,24,25(OH)3D respectively. However, we cannot test
this hypothesis in the present study because there are
insufficient samples remaining and because we do not
yet have an analytical method that is able to determine
the concentration of downstream metabolites of 25OHD.
Despite differences in 25OHD-t1/2, there was no difference
in 25OHD concentrations between BD and LCK children.
This might be explained by the likelihood that endo-
genous vitamin D production was not limiting in these
children who were living in a tropical country with year-
round abundant UVB-containing sunshine.
Another finding of this study is that in addition to
the small amounts of Ca present in the children’s diet,
there was a high prevalence of factors that decrease
Ca absorption, such as infection and enteropathy, which
may further reduce Ca supply. This study demonstrated
that over 80% of the children were infected with H. pylori.
This is in keeping with previous Gambian studies that
have shown that the prevalence of H. pylori infection
increases to w80% throughout infancy (!2.5 years) (34).
Eighty-eight percentage of the children showed signs
of intestinal malabsorption as indicated by a low percen-
tage recovery of mannitol (a passively absorbed sugar).
Intestinal malabsorption is often observed in populations
in which diarrhoeal diseases are common. Numerous
diarrhoeal episodes are thought to result in partial villus
atrophy, which leads to a reduction in intestinal absorp-
tion ability of minerals such as Ca.http://www.endocrineconnections.org
DOI: 10.1530/EC-13-0070
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Published by Bioscientifica LtdI-FGF23 and C-FGF23 concentrations had different
biochemical predictors and were poorly correlated with
each other. 1,25(OH)2D was the strongest negative
predictor of I-FGF23 concentration, in line with the
known suppressive action of FGF23 on CYP27B1. By
contrast, sTfR, high concentrations of which describe
poor iron status, and not 1,25(OH)2D was the strongest
predictor of C-FGF23 concentration. This supports
previous reports from the Gambia and elsewhere showing
an association between C-FGF23 concentration and
various markers of poor iron status (2, 14, 35) and suggests
that the interpretation of data from C-FGF23 assays should
be made with caution in populations with a high pre-
valence of iron deficiency. A recent study in rats has
shown that iron deficiency had effects on Fgf23 gene
expression similar to those of oxygen deprivation,
suggesting a mechanism that iron deficiency may result
in hypoxia resulting in an increased Fgf23 gene expression
due to hypoxia-induced factors (15). It has been suggested
that an increased production of FGF23 caused by poor
iron status is balanced by an increased cleavage of the
I-FGF23 protein (16, 17). This would result in increased
concentrations of cleaved and biologically inactive C- and
N-terminal fragments but an unchanged concentration
of the I-FGF23 and active FGF23 hormone. Such a
mechanism would explain why the LCC children showed
no signs of phosphate wasting or rickets, despite having
prolonged elevated concentrations of C-FGF23. An
additional element to consider is the possible antagonistic
effects of C-FGF23 fragments on the FGFR. Goetz et al. (10)
showed in otherwise healthy mice that an injection of
a recombinant C-terminal fragment results in hyper-
phosphataemia due to a decreased urinary P excretion.
However, the question remains as to why LCC children
have a higher prevalence of iron deficiency than their
peers. This may be an indication of a genetic disorder of
iron metabolism such as thalassemia or sickle cell trait,
both of which are known to be prevalent in Gambia (36).
The initial cause of an elevated C-FGF23 concentration
in BD children and its role in the pathogenesis of rickets
are unclear. Moreover, differences in FGF23 concen-
trations do not seem to affect 25OHD-t1/2, despite the
described roles of FGF23 in CYP enzyme activity (6, 7).
In summary, this study demonstrated that elevated
plasma C-FGF23 concentrations normalised over time in
Gambian children with a history of rickets but not in
apparently healthy local children, suggesting that the
aetiology of a raised FGF23 concentration is different in
these two groups. This study adds to the growing literature
that C-FGF23 and I-FGF23 assays are not alwaysThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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9–10 3 :9comparable (37) and reflect different components of the
FGF23 pathway and that markers of iron status are the
strongest predictors of C-FGF23 concentration but not of
I-FGF23 concentration. Finally, this study demonstrated
that children with resolved rickets had a shorter 25OHD-
t1/2 than local children, suggesting a long-standing
increased expenditure of 25OHD.Declaration of interest
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